BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16607614)

  • 1. Extracellular tumor DNA in plasma and overall survival in breast cancer patients.
    Garcia JM; Garcia V; Silva J; Peña C; Dominguez G; Sanchez A; Sanfrutos L; Provencio M; Millan I; Chaparro D; España P; Bonilla F
    Genes Chromosomes Cancer; 2006 Jul; 45(7):692-701. PubMed ID: 16607614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.
    Silva JM; Silva J; Sanchez A; Garcia JM; Dominguez G; Provencio M; Sanfrutos L; Jareño E; Colas A; España P; Bonilla F
    Clin Cancer Res; 2002 Dec; 8(12):3761-6. PubMed ID: 12473587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
    Shao ZM; Wu J; Shen ZZ; Nguyen M
    Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations.
    Silva JM; Dominguez G; Garcia JM; Gonzalez R; Villanueva MJ; Navarro F; Provencio M; San Martin S; España P; Bonilla F
    Cancer Res; 1999 Jul; 59(13):3251-6. PubMed ID: 10397273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsatellite alterations plasma DNA of primary breast cancer patients.
    Shaw JA; Smith BM; Walsh T; Johnson S; Primrose L; Slade MJ; Walker RA; Coombes RC
    Clin Cancer Res; 2000 Mar; 6(3):1119-24. PubMed ID: 10741742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.
    van Nes JG; Putter H; Julien JP; Tubiana-Hulin M; van de Vijver M; Bogaerts J; de Vos M; van de Velde CJ;
    Breast Cancer Res Treat; 2009 May; 115(1):101-13. PubMed ID: 18484198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
    Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
    Schwarzenbach H; Müller V; Stahmann N; Pantel K
    Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
    Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer.
    Chen X; Bonnefoi H; Diebold-Berger S; Lyautey J; Lederrey C; Faltin-Traub E; Stroun M; Anker P
    Clin Cancer Res; 1999 Sep; 5(9):2297-303. PubMed ID: 10499596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer.
    Utada Y; Emi M; Yoshimoto M; Kasumi F; Akiyama F; Sakamoto G; Haga S; Kajiwara T; Nakamura Y
    Clin Cancer Res; 2000 Aug; 6(8):3193-8. PubMed ID: 10955803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
    Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
    Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients.
    Austrup F; Uciechowski P; Eder C; Böckmann B; Suchy B; Driesel G; Jäckel S; Kusiak I; Grill HJ; Giesing M
    Br J Cancer; 2000 Dec; 83(12):1664-73. PubMed ID: 11104564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Peripheral blood mutated p53 DNA and its clinical value in human breast cancer].
    Di GH; Liu G; Wu J; Shen ZZ; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2003 Mar; 25(2):137-40. PubMed ID: 12795838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
    Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
    Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.